ClinicalTrials.gg
RecruitingNCT07262333Updated Aug 13, 2026

A Trial of Hydroxynidone Capsules in Single-dose Administration for Patients With Renal Insufficiency

A Phase 1 interventional study of Hydronidone capsules in Renal Insufficiency Chronic, sponsored by Beijing Continent Pharmaceutical Co, Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Beijing Continent Pharmaceutical Co, Ltd. (part of GNI Group Ltd.) · Phase 1, Interventional, and Other

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 245 studies in Renal Insufficiency, Chronic with a site in China — 94 open to participants now, 107 under way, 17 of them phase 3. Renal Insufficiency, Chronic · China.

Planned enrollment
124th of 164
56 · median 182
Started
2025
with 26 others
Phase 1
20 of 245
10 open now
Primary completion
2026-12
later than 45 of 106 live
Registered
207th of 245
by date

Among the 245 studies in Renal Insufficiency, Chronic with a site in China, this one is the 124th largest by planned enrollment of the 164 interventional ones that give a count, is one of 27 that started in 2025, is one of 20 in phase 1, reaches primary completion later than 45 of the 106 other live ones, and was the 207th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

94 of the 245 studies in Renal Insufficiency, Chronic with a site in China are open now. Recruiting first, the newest first:

88 more — sign in →

All 94 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 245 studies in Renal Insufficiency, Chronic with a site in China, or all of them as a file.
02

Study summary

Hydronidone capsules are pyridinone-based small molecule compounds. Hydronidone has not been approved for commercial sale both domestically and internationally. The applicant has completed the preliminary Phase I and Phase II clinical trials. The results showed that Hydronidone is a safe and effective drug for treating liver fibrosis in chronic hepatitis B, and it has good safety and tolerability.

Based on the preliminary clinical research, a special population study has been initiated. The aim is to investigate the pharmacokinetic differences and safety of honginone capsules in patients with renal insufficiency and healthy subjects, in order to provide a basis for the clinical medication of patients with renal dysfunction.

03

Conditions studied

  • Renal Insufficiency Chronic

Keywords

  • Hydroxynidone
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subjects must meet all of the following criteria to be eligible for inclusion:
  • (1) Healthy Chinese subjects, with an estimated (absolute eGFR) meeting the following conditions: ≥ 90 mL/min and \< 130 mL/min; (limited to healthy subjects)
  • (2) Patients diagnosed with renal dysfunction, with the estimated glomerular filtration rate (absolute eGFR) for mild, moderate, and severe renal dysfunction meeting the following standards respectively: 1. Mild renal dysfunction 60-89 mL/min; 2. Moderate renal dysfunction 30-59 mL/min; 3. Severe renal dysfunction 15-29 mL/min; (limited to patients with renal dysfunction)
  • (3) Age 18-70 years old, inclusive of 18 years and 70 years old;
  • (4) Weight: Male ≥ 50 kg, female ≥ 45 kg, 18 ≤ ≤ 28 (BMI = weight (kg) / height2 (m2));
  • (5) During the 24 hours before the start of the trial to the end of the trial, the subjects agree to quit smoking, alcohol, fruit juices, caffeine, and tea;
  • (6) Before the trial, they have fully understood the nature, significance, possible benefits, possible inconveniences, and potential risks of the trial, and voluntarily participated in this clinical trial, can communicate well with the researchers, comply with all the requirements of the entire study, and have the ability to understand and sign the written form.

Exclusion criteria

Exclusion Criteria:

  • The following conditions must be met for a subject to be eligible for this trial:
  • (1) If the subject has participated in any other clinical trial within the three months prior to the trial;
  • (2) If the subject has any disease that may affect the safety of the trial or the body's process of the drug, excluding renal insufficiency, including but not limited to: previous or existing diseases of the heart, liver, digestive tract, immune system and respiratory system (especially any gastrointestinal diseases that affect drug absorption, such as irritable bowel syndrome symptoms, intestinal diseases or inflammatory bowel disease history, active pathological bleeding (such as peptic ulcers), urticaria, epilepsy, allergic rhinitis, eczematous dermatitis, asthma, etc.); (limited to patients with renal insufficiency);
  • (3) If the subject has any disease that may affect the safety of the trial or the body's process of the drug, including but not limited to: previous or existing diseases of the heart, liver, kidney, endocrine, digestive tract, immune system and respiratory system (especially cardiovascular diseases including those with cardiovascular disease risk, any gastrointestinal diseases that affect drug absorption (such as irritable bowel syndrome symptoms, intestinal diseases or inflammatory bowel disease history), active pathological bleeding (such as peptic ulcers), urticaria, epilepsy, allergic rhinitis, eczematous dermatitis, asthma, etc.); (limited to healthy subjects);
  • (4) If the subject has an allergic constitution: if there is a history of allergy to two or more drugs (including the trial drug), food, or lactose intolerance;
  • (5) If the subject has used any drugs that inhibit or induce the liver's metabolism of the drug within 28 days before taking the study drug (common liver enzyme inducers: barbiturates, carbamazepine, amiloride, griseofulvin, amitriptyline, phenytoin, grumet, rifampicin, dexamethasone; common liver enzyme inhibitors: chlorpromazine, cimetidine, ciprofloxacin, metronidazole, chloramphenicol, isoniazid, sulfonamide drugs);
  • (6) If the subject has used drugs that inhibit or induce SULT and UGT enzymes within 7 days before taking the study drug and cannot stop the use;
  • (7) If the subject cannot tolerate venipuncture and/or has a history of fainting or needle shock;
  • (8) If the subject has long-term excessive consumption of tea, coffee or caffeinated beverages (more than 8 cups per day, 1 cup = 250 mL) in the past; or if within 24 hours before the first administration of the study drug, the subject consumed any food or beverage that inhibits or induces liver metabolic enzymes (such as grapefruit, mango, dragon fruit, grape juice, orange juice, etc., which contain rich flavonoids or citrus glycosides compounds); or if within 24 hours before the first administration of the study drug, the subject took any product containing alcohol;
  • (9) If the subject has consumed blood or had a large amount of bleeding (more than 450 mL) within 3 months before the first administration of the study drug, or plans to donate blood or blood components during or after the study;
  • (10) If the subject has donated blood or had a large amount of bleeding (more than 450 mL) within 3 months before the first administration of the study drug, or plans to donate blood or blood components during or after the study;
  • (11) If the subject has acute diseases during the screening stage of the study or before taking the study drug;
  • (12) If the subject has consumed foods or beverages that inhibit or induce liver metabolic enzymes within 24 hours before the first administration of the study drug (such as grapefruit, mango, dragon fruit, grape juice, orange juice, etc., which contain rich flavonoids or citrus glycosides compounds);
  • (13) If the subject is pregnant or breastfeeding, and the subject (or their partner) has a pregnancy plan during and after the study, and does not agree to use non-drug measures for during the study period;
  • (14) (Medical Inquiry) Those who underwent surgery within three months prior to the screening period, or those planning to undergo surgery during the study period, and those who have undergone surgeries that may affect drug absorption, distribution, metabolism, and excretion;
  • (15) Those with a history of drug use or drug abuse;
  • (16) Those who smoked more than 5 cigarettes per day within 14 days prior to the screening, or those who cannot stop using any tobacco products during the trial;
  • (17) Those who smoked or used any tobacco products during the screening to admission period;
  • (18) During the screening period, abnormalities in physical examination, , and laboratory tests (including routine blood and urine tests, coagulation function, and pregnancy test for women of only) that are judged by the investigator as (excluding those caused by renal insufficiency). For liver function tests: > 3× or AST > 3×ULN or > 2×ULN or D-BIL > 2×ULN; for lipid tests: TG ≥ 5.6 mmol/L; for serum electrolyte tests (K+, Na+, Cl-, Ca2+): abnormalities indicating hyperkalemia or a tendency toward acidosis (limited to patients with renal insufficiency).
  • (19) Those whose physical examination, vital sign measurement, electrocardiogram examination, laboratory tests [blood routine, urine routine, blood biochemistry, coagulation function, blood pregnancy (only for women of childbearing age)] as determined by the researchers show abnormal results with clinical significance; (for healthy subjects)
  • (20) Those with positive nicotine test results;
  • (21) Those with alcohol breath test results greater than 0.0 mg/100 ml;
  • (22) Those with positive urine drug screening results;
  • (23) Those with positive surface antigen, or antibody, or syphilis spirochete antibody, or antibody test results positive;
  • (24) Those who, as determined by the researchers, have any situation that may affect the subject's provision of or compliance with the trial protocol, or who participating in the trial may affect the trial results or their own safety.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    Control group (healthy individuals)

    On the morning of Day 1, take 90mg of hydronidone capsules on an empty stomach.

    Drug: Hydronidone capsules

  • Experimental
    The group of patients with mild renal insufficiency(eGFR 60~89 mL/min)

    On the morning of Day 1, take 90mg of hydronidone capsules on an empty stomach.

    Drug: Hydronidone capsules

  • Experimental
    The group of patients with moderate renal insufficiency(eGFR 30~59 mL/min)

    On the morning of Day 1, take 90mg of hydronidone capsules on an empty stomach.

    Drug: Hydronidone capsules

  • Experimental
    The group of patients with severe renal insufficiency(eGFR 15~29 mL/min)

    On the morning of Day 1, take 90mg of hydronidone capsules on an empty stomach.

    Drug: Hydronidone capsules

Interventions

06

What researchers measure

Primary outcomes

  1. The plasma drug concentrations of hydronidone and its metabolites M3 and M4(AUC0-∞)

    Time frame: 48 hours after administration

  2. The free plasma concentration of hydronidone

    Time frame: 48 hours after administration

  3. The urine drug concentrations of hydronidone and its metabolites M3 and M4

    Time frame: 48 hours after administration

  4. The plasma drug concentrations of hydronidone and its metabolites M3 and M4(AUC%Extrap)

    Time frame: 48 hours after administration

  5. The plasma drug concentrations of hydronidone and its metabolites M3 and M4( AUC0-t)

    Time frame: 48 hours after administration

  6. The plasma drug concentrations of hydronidone and its metabolites M3 and M4(CL/F)

    Time frame: 48 hours after administration

  7. The plasma drug concentrations of hydronidone and its metabolites M3 and M4(Vd/F)

    Time frame: 48 hours after administration

  8. The plasma drug concentrations of hydronidone and its metabolites M3 and M4(Cmax)

    Time frame: 48 hours after administration

  9. The plasma drug concentrations of hydronidone and its metabolites M3 and M4(T1/2)

    Time frame: 48 hours after administration

  10. The plasma drug concentrations of hydronidone and its metabolites M3 and M4(λz)

    Time frame: 48 hours after administration

  11. The plasma drug concentrations of hydronidone and its metabolites M3 and M4(Tmax)

    Time frame: 48 hours after administration

Secondary outcomes

  1. Safety indicator: Any adverse event

    Adverse Event (AE) is defined as any untoward medical occurrence during drug clinical trials, drug therapy, or medical procedures, regardless of its causal relationship to the drug used.

    Time frame: 72 hours after administration

  2. Safety indicator: B-ultrasound examination(liver)

    Time frame: 72 hours after administration

  3. Safety indicator: B-ultrasound examination(gallbladder)

    Time frame: 72 hours after administration

  4. Safety indicator: B-ultrasound examination(pancreas)

    Time frame: 72 hours after administration

  5. Safety indicator: B-ultrasound examination(spleen)

    Time frame: 72 hours after administration

  6. Safety indicator: B-ultrasound examination(kidneys)

    Time frame: 72 hours after administration

  7. Safety indicators:12-lead electrocardiogram examination.

    The 12-lead electrocardiogram records the electrical activity of the heart through 12 different lead positions, and is the most commonly used and fundamental non-invasive examination method for diagnosing heart diseases.A 12-lead ECG examines P waves, PR intervals, QRS complexes, ST segments, T waves, QT intervals, and other ECG waves and intervals.

    Time frame: 72 hours after administration

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.

Of 77 industry-sponsored phase 1 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's planned 11 months is above that.

Counting every sponsor, half of 109 studies reached it within 12 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Dec 3, 2025
StartActual
Dec 25, 2025
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07262333
Responsible party
Sponsor
First posted
Dec 3, 2025
Start date
Dec 25, 2025
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Aug 13, 2026

Study contacts

Ling Zhang
Contact
zhangling@bjcontinent.com
+86-13501209210
shaojun Shi
principal investigator · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hydronidone

Start the discussion